Top news
HIV

CROI 2024 - Exchange: Aging

Mehr lesen
Top news
HIV

CROI 2024 - Exchange: Weight

Mehr lesen
Top news
HIV

Biktarvy Experten Statement 2023

HIV-Expert*innen aus Deutschland, Österreich und der Schweiz beleuchten Real World Studiendaten und Real World Erfahrungen mit Biktarvy

Mehr lesen
Top news
HIV

IAS 2023 - Exchange: Gewichtsveränderung

Mehr lesen
Top news
HIV

IAS 2023 - Exchange: Rapid Start

Mehr lesen
Top news
HIV

IAS 2023 - Exchange: Resistenzen

Mehr lesen
Top news
HIV

Rieke, A. et al: Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in Treatment-Experienced (TE) People With HIV With a History of CKD

02.-05.11.2023 / ID Week

Mehr lesen
Top news
HIV

Sabranski, M. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort.

18.-21.10.2023 / EACS 2023

Mehr lesen
Top news
HIV

Esser, S. et al: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study.

18.-21.10.2023 / EACS 2023

Mehr lesen
Top news
HIV

Andreatta, K. et al: Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG) Based 3 Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence

11.-15.10.2023 / ID Week

Mehr lesen